🇪🇺 Adlumiz in European Union

EMA authorised Adlumiz on 16 November 2017

Marketing authorisation

EMA — authorised 16 November 2017

  • Application: EMEA/H/C/003847
  • Marketing authorisation holder: Helsinn Birex Pharmaceuticals Ltd.
  • Local brand name: Adlumiz
  • Indication: Treatment of anorexia, cachexia or unintended weight loss in adult patients with non-small cell lung cancer (NSCLC)
  • Status: rejected

Read official source →

Adlumiz in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Adlumiz approved in European Union?

Yes. EMA authorised it on 16 November 2017.

Who is the marketing authorisation holder for Adlumiz in European Union?

Helsinn Birex Pharmaceuticals Ltd. holds the EU marketing authorisation.